Hyphen BioMed Overview
- Founded
-
1999
- Status
-
Acquired/Merged
- Employees
-
80
- Latest Deal Type
-
M&A
- Financing Rounds
-
2
Hyphen BioMed General Information
Description
Operator of a technical and innovative, scientific company intended to propose a full line of diagnostic and research reagents to be distributed worldwide. The company's diagnostic and research reagents are available worldwide, through a network of specialised distributors, or directly from the company and its laboratories are equipped with analytical instruments and with highly performing manufacturing machines and quality control analyzers enabling the company to conceive, manufacture, market and develop research and biomedical in vitro diagnostic reagents for the exploration of Thrombosis, Haemostasis and Auto-Immunity. It owns a complete range of analytical equipment for immunological, clotting and chromogenic methods, cell culture, production of recombinant proteins, engineering and purification of proteins from plasma or biological extracts.
Contact Information
Website
www.hyphen-biomed.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Formerly PE-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Other Chemicals and Gases
Biotechnology
Parent Company
Primary Office
- ZAC Neuville-Université
- 155 Rue d'Eragny
- 95000 Neuville-sur-Oise
- France
Hyphen BioMed Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Hyphen BioMed Patents
Hyphen BioMed Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2007262869-A1 | Method and kit for the detection of heparin-dependent antibodies and the diagnosis of immune or autoimmune pathologies potentiated by heparin such as heparin-induced thrombocytopenia | Inactive | 23-Jun-2006 | 000000000 | |
| CA-2655582-A1 | Method and kit for the detection of heparin-dependent antibodies and the diagnosis of immune or autoimmune pathologies potentiated by heparin such as heparin-induced thrombocytopenia | Active | 23-Jun-2006 | 000000000 | |
| CA-2655582-C | Method and kit for the detection of heparin-dependent antibodies and the diagnosis of immune or autoimmune pathologies potentiated by heparin such as heparin-induced thrombocytopenia | Active | 23-Jun-2006 | 000000000 | |
| EP-2030017-B1 | Method and kit for the detection of heparin-dependent antibodies and the diagnosis of immune or autoimmune pathologies potentiated by heparin such as heparin-induced thrombocytopenia | Active | 23-Jun-2006 | 000000000 | 0 |
| EP-2030017-A1 | Method and kit for the detection of heparin-dependent antibodies and the diagnosis of immune or autoimmune pathologies potentiated by heparin such as heparin-induced thrombocytopenia | Active | 23-Jun-2006 | G01N33/86 |
Hyphen BioMed Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Anne-Marie Vissac | Founder | ||
| Jean Amiral Ph.D | Co-Founder, President & Scientific and Research Director |
Hyphen BioMed Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Hyphen BioMed Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|